RZLT
Rezolute, Inc. Common Stock (NV)
stockNASDAQ
rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases. rezolute is advancing a diversified pipeline including: rz358 (phase 2), an antibody for the ultra-orphan indication of congenital hyperinsulinism (chi) with an abbreviated path-to-market strategy; ab101 (phase 1), a once-weekly injectable basal insulin with the potential to transform the treatment landscape in diabetes management by reducing the therapeutic burden for patients and improving compliance; and rz402 (plan to file ind in h2 2018), a plasma kallikrein inhibitor (pki) targeting diabetic macular edema (dme). for more information, visit: www.rezolutebio.com.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.88 | 2026-11-06 | -5.93% | 0.256 |
| 1M | 4.61 | 2026-10-13 | -20.82% | 1.597 |
| 3M | 4.60 | 2026-08-13 | -20.65% | 1.528 |
| 6M | 3.33 | 2026-05-13 | +9.61% | 1.483 |
| 1Y | 9.94 | 2025-11-13 | -63.28% | 1.240 |
| 2Y | 5.64 | 2024-11-13 | -35.28% | — |
| 5Y | 6.30 | 2021-11-12 | -42.06% | 0.822 |
Rezolute, Inc. Common Stock (NV) (NASDAQ:RZLT) stock price today is $3.65, and today's volume is 5,736,255. RZLT is down 5.685% today. The 30 day average volume is 1.52M. RZLT market cap is $353.06M with 96.73M shares outstanding.